Selected Publications

Academic Article

Year Title Altmetric
2022 Challenges of Assessing Resident Competency in Well-Being: Development of the Psychiatry Milestones 2.0 Well-Being SubcompetencyAcademic Medicine.  97:351-356. 2022
2021 Psychiatry Milestones 2.0: Using the Supplemental Guide to Create a Shared Model of the Development of Professional Identity and ExpertiseAcademic Psychiatry.  45:500-505. 2021
2021 Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.Journal of Clinical Psychiatry.  82. 2021
2021 Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial 2021
2021 Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depressionPsychiatry Research.  296. 2021
2021 Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depressionAnnals of Clinical Psychiatry.  33:18-26. 2021
2020 Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With DepressionAmerican Journal of Geriatric Psychiatry.  28:933-945. 2020
2020 Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive DisorderPsychiatry Research.  290. 2020
2020 150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression 2020
2019 Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBMC Psychiatry.  19. 2019
2019 Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapiesJournal of Psychiatric Research.  114:211-213. 2019
2019 Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled studyJournal of Psychiatric Research.  111:59-67. 2019
2019 Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trialJournal of Clinical Psychiatry.  80. 2019
2015 How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development 2015
2014 Secondary Psychosis 3 Months Prior to the Overt Symptoms of Multiple Myeloma 2014
2012 How Biomarkers Will Change Psychiatry. Part II 2012
2012 How Biomarkers Will Change Psychiatry 2012
2011 Phase I Trials 2011
2011 Phase I Trials 2011
2011 CYP 2D6 PM Status and Antidepressant Response to Nortriptyline and VenlafaxineJournal of Clinical Psychopharmacology.  31:143-145. 2011
2010 The Role of Benzodiazepines in the Treatment of Anxiety Disorders: A Clinical ReviewPsychiatric Annals.  40:605-610. 2010
2010 The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review 2010
2010 Twenty Percent of a Representative Sample of Patients Taking Bupropion Have Abnormal, Asymptomatic Electroencephalographic FindingsJournal of Clinical Psychopharmacology.  30:312-317. 2010
2008 Duloxetine for the treatment of generalized anxiety disorder: a reviewNeuropsychiatric Disease and Treatment.  23-23. 2008
2008 A 19-year-old Black Woman with Psychotic and Depressive SymptomsPsychiatric Annals.  38. 2008
2000 Alaninyltryptophan hydrate, glycyltryptophan dihydrate and tryptophylglycine hydrateActa Crystallographica Section C: Crystal Structure Communications.  56:e469-e471. 2000


Year Title Altmetric
2012 Phase I Trials 2012

Education And Training

  • Doctor of Osteopathy in Osteopathic Medicine / Osteopathy, University of Medicine and Denistry of New Jersey 2005
  • Bachelor of Arts in Chemistry, Rutgers University : Newark 2001
  • Full Name

  • Matthew Macaluso